Anne Corbett, Millie Sander-Long, Nicholas J Ashton, Hanna Huber, Jakub Vavra, Luisa Sophie Braun-Wohlfahrt, Henrik Zetterberg, Laia Montoliu-Gaya, Jeffrey Cummings, Freya Bateman, Christine Davis, Clive Ballard
7 min
As Alzheimer's disease (AD) diagnostics shift toward blood-based biomarkers, a major bottleneck remains the requirement for clinic visits, which limits access for the vast majority of individuals with early cognitive impairment. This study investigated whether a self-administered, at-home capillary blood (fingerprick) sampling method could provide reliable biomarker data. Researchers recruited 174 participants—ranging from cognitively normal to those with dementia—to test the feasibility of measuring p-tau217 and GFAP via dried blood spots. They compared these remote results against venous blood samples and evaluated how well these biomarkers correlated with standardized cognitive and functional assessments.
The study demonstrated that at-home capillary blood sampling is both feasible and highly acceptable to older adults, with 80% of participants completing the test without assistance. The capillary-derived p-tau217 and GFAP levels showed strong correlations with venous blood measurements. Furthermore, these biomarkers were significantly associated with cognitive performance and functional impairment. By applying a dual-threshold approach—combining biomarker levels with computerized memory testing—the researchers successfully identified high-risk and low-risk groups, suggesting this method could serve as a scalable triage tool to prioritize patients for further clinical evaluation.
An interesting divergence was noted between the two biomarkers. While both were associated with cognitive decline, they appeared to reflect different underlying processes. GFAP positivity was strongly linked to cardiovascular risk factors, such as a history of heart disease, whereas p-tau217 was not. This suggests that while p-tau217 is a specific marker for AD-related pathology, GFAP may provide additional, complementary information regarding vascular contributions to cognitive impairment.
This research provides a proof-of-concept for a decentralized diagnostic model. By enabling individuals to screen for AD risk from home, this technology could drastically reduce the burden on specialist clinics and improve the efficiency of clinical trial recruitment. It offers a scalable, low-cost pathway to identify those who truly need advanced diagnostic services, potentially reaching the large population currently excluded from the traditional diagnostic pipeline.
Blood biomarkers are rapidly becoming established for Alzheimer’s Disease (AD) diagnosis. However, there is a need for more scalable tools to reach the 99% of individuals with early cognitive impairment who are not seen in specialist healthcare services. A recent study validated a capillary blood sampling technique to detect the p-tau217 and GFAP biomarkers. Here we used our PROTECT research study to show that these biomarkers, when collected using self-administered fingerprick tests, correlate well with venous blood biomarkers and with cognition and function in 174 people who were cognitively normal or who had mild cognitive impairment or AD. They can be used in combination with computerised cognitive testing to identify people with the highest risk of AD. The GFAP biomarker appears to be associated with vascular risk, unlike p-tau217. Patient feedback indicates high acceptability and usability of the capillary test method, giving confidence in the feasibility of this technology. The work suggests that capillary blood biomarkers could be used to enable triage of people with varying levels of risk of AD in clinical practice and for clinical trials, and could be used outside of clinical settings. This study shows that capillary blood sampling at home using fingerprick testing is feasible and provides reliable biomarkers for Alzheimer’s Disease. They correlate with cognition and can identify people at highest risk of Alzheimer’s Disease.
Alex: That's where the technology becomes important. They use an extremely sensitive laboratory method called a single molecule array — or "Simoa" for short. The name tells you something: it can detect individual protein molecules. Imagine a tool sensitive enough to find a single grain of sand on a beach. That's roughly the level of precision involved. The blood is collected on a small card as a dried spot, mailed to a lab, and analyzed there.
Sam: So the person at home doesn't need any special equipment — just the card and the fingerprick?
Alex: Exactly. And the study actually tested whether real people could manage this on their own. Around 80% of participants completed the test entirely without any outside help. Most described it as easy and painless, and noted it saved them the stress and time of traveling to a clinic.
Sam: That's a higher success rate than I'd have expected for a medical test done at home.
Alex: It's a meaningful result, and it speaks to something the researchers clearly cared about — not just whether the science works, but whether ordinary people will actually use it. Around 78% said they'd be willing to incorporate this kind of test into their regular healthcare routine. A test that works in a lab but that nobody does at home isn't useful.
Sam: Right. So the human experience is just as important as the chemistry. How do they know the test is actually accurate, though?
Alex: They used a standard tool for evaluating diagnostic tests called a Receiver Operating Characteristic curve — or ROC curve. Here's the idea: any test involves a trade-off. If you set the bar very low for flagging someone as high-risk, you'll catch almost everyone who truly is at risk, but you'll also flag a lot of healthy people unnecessarily. Set the bar too high, and you miss people who need help. The ROC curve maps out that trade-off across every possible threshold, and gives you a single number — the area under the curve — that summarizes how well the test separates sick from healthy. The study found both biomarkers performed significantly better than chance.
Sam: But it's not meant to be a final diagnosis on its own?
Alex: That's a key point the researchers are careful to make. A screening tool like this is a first step — a way to sort people into "needs more investigation" and "probably fine for now." It's not a verdict. Anyone who tests positive still needs a full clinical evaluation to understand what's actually going on.
Sam: You mentioned earlier that GFAP and p-tau217 sometimes flag different people. Can you explain that?
Alex: Yes, and this is where it gets interesting. p-tau217 is quite specific to Alzheimer's pathology — the biological changes that are directly associated with that disease. GFAP, on the other hand, tends to flag people whose brains are under stress for other reasons — particularly vascular factors, meaning issues related to blood flow and heart health. The researchers found that GFAP positivity showed links to heart disease and attentional problems, suggesting it's picking up on a different kind of brain strain.
Sam: So p-tau217 is the specialist for Alzheimer's, and GFAP casts a wider net for general brain health.
Alex: That's a fair summary. For clinical trials specifically targeting Alzheimer's, p-tau217 is the preferred tool. But for a doctor trying to understand all-cause cognitive decline — the full range of reasons someone's thinking might be deteriorating — GFAP provides useful additional context.
Sam: The paper also mentions something called "dual thresholding." What does that mean practically?
Alex: Think of it like sorting mail into three piles. The first pile is urgent — these letters need immediate attention. The third pile is clearly low priority — set it aside. The middle pile is uncertain — keep an eye on it. Dual thresholding works the same way. One cutoff identifies people at high enough risk to refer to a specialist immediately. A second cutoff identifies people clearly low-risk. Everyone in between gets monitored over time. It's a much more efficient use of limited medical resources than the current approach, which is essentially "either you get a specialist or you don't."
Sam: Are there limitations the researchers flag?
Alex: They're candid about several. The 80% completion rate is promising, but they acknowledge the instructions need to be clearer to push that number higher — because a test is only as good as the sample it receives. They also stress that the sensitivity of these markers isn't perfect, and that the findings need to be validated in larger, more diverse groups before this becomes standard practice. This is a demonstration of feasibility, not a finished product.
Sam: So it's a meaningful step toward making early detection accessible to the people currently being missed — but with more work still ahead.
Alex: That's the right framing. The vision here is a future where monitoring brain health is as routine as checking blood pressure — something you can do at home, that feeds into a system that knows when to escalate and when to reassure. This study suggests that vision is technically within reach. Getting it there will require careful refinement and rigorous validation, but the foundation looks solid.
Sam: That's a genuinely different way of thinking about Alzheimer's care — from reactive to proactive.
Alex: And that shift, if it holds up, could matter enormously for the people who currently fall through the gaps. Thanks for listening to ResearchPod.